№ lp_2_2_04719
File format: docx Character count: 6074 File size: 37 KB
Year: 2026
Region / City: United Kingdom
Subject: Medicine Guidelines
Document Type: Medical Guidelines
Organization: NHS
Author: Not specified
Target Audience: Healthcare professionals (psychiatrists, pharmacists)
Effective Period: Indefinite, for use with Trevicta®
Approval Date: Not specified
Date of Changes: Not specified
Context Description: Medical guideline on the administration of Trevicta® long-acting injection for patients transitioning from Xeplion® in the UK, specifically for schizophrenia treatment.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Shared Care Protocol for Paliperidone Palmitate Long-Acting Injection in Adult Services
Document type: Shared care protocol
Medicine: Paliperidone palmitate long-acting injection
Indication: Maintenance treatment of schizophrenia
Population: Adults aged 18 years and over
Healthcare setting: Secondary and primary care
Intended users: NHS healthcare professionals
Initiation of treatment: Secondary care mental health services
Shared care commencement: After approximately 12 weeks when dose is optimised
Dosage forms: 1-monthly, 3-monthly and 6-monthly long-acting injections
Renal impairment restriction: Not recommended in moderate or severe renal impairment (creatinine clearance <50 ml/min)
Version: v4.0
Replaces version: v3.0
Clinical content last reviewed: January 2024
Next review date: June 2026
Approving bodies: GM CRG, GMMMG, CEGC
Approval dates: 14 May 2024; 13 June 2024; 20 June 2024
Geographical scope: NHS Greater Manchester
Usage restriction: Non-commercial, non-marketing use only
Informed Consent for Medication: Invega Trinza (Paliperidone Palmitate) – State of Wisconsin Form F-24277 (05/2024)
Year: 2024
State: Wisconsin
Country: United States
Issuing Authority: Department of Health Services, Division of Mental Health and Substance Abuse Services
Form Number: F-24277
Legal References: 42 CFR 483.420(a)(2); DHS 134.31(3)(o); DHS 94.03 & 94.09; §§ 51.61(1)(g) & (h)
Document Type: Informed Consent Form
Medication Category: Atypical Antipsychotic
Medication Name: Invega Trinza (paliperidone palmitate)
Dosage Information Last Revised: 05/09/2016
Administration Route: Intramuscular injection
Intended Use: Psychotropic medication treatment with DSM-5 diagnosis or diagnostic impression
Population: Patients / Clients receiving mental health services
Record Status: Maintained in client record and accessible to authorized users
Voluntary Status: Completion voluntary; court order required if consent not given unless emergency
Shared Care Protocol for Paliperidone Palmitate Long-Acting Injection in Adult Services
Document type: Shared care protocol
Medicine: Paliperidone palmitate long-acting injection
Indication: Maintenance treatment of schizophrenia
Population: Adults aged 18 years and over
Healthcare setting: Secondary and primary care
Intended users: NHS healthcare professionals
Initiation of treatment: Secondary care mental health services
Shared care commencement: After approximately 12 weeks when dose is optimised
Dosage forms: 1-monthly, 3-monthly and 6-monthly long-acting injections
Renal impairment restriction: Not recommended in moderate or severe renal impairment (creatinine clearance <50 ml/min)
Version: v4.0
Replaces version: v3.0
Clinical content last reviewed: January 2024
Next review date: June 2026
Approving bodies: GM CRG, GMMMG, CEGC
Approval dates: 14 May 2024; 13 June 2024; 20 June 2024
Geographical scope: NHS Greater Manchester
Usage restriction: Non-commercial, non-marketing use only
Informed Consent for Medication: Invega Trinza (Paliperidone Palmitate) – State of Wisconsin Form F-24277 (05/2024)
Year: 2024
State: Wisconsin
Country: United States
Issuing Authority: Department of Health Services, Division of Mental Health and Substance Abuse Services
Form Number: F-24277
Legal References: 42 CFR 483.420(a)(2); DHS 134.31(3)(o); DHS 94.03 & 94.09; §§ 51.61(1)(g) & (h)
Document Type: Informed Consent Form
Medication Category: Atypical Antipsychotic
Medication Name: Invega Trinza (paliperidone palmitate)
Dosage Information Last Revised: 05/09/2016
Administration Route: Intramuscular injection
Intended Use: Psychotropic medication treatment with DSM-5 diagnosis or diagnostic impression
Population: Patients / Clients receiving mental health services
Record Status: Maintained in client record and accessible to authorized users
Voluntary Status: Completion voluntary; court order required if consent not given unless emergency
Topics: Trevicta Paliperidone Palmitate